Literature DB >> 16033683

New-onset diabetes after transplantation.

Martha Pavlakis1.   

Abstract

New-onset diabetes after transplantation (NODAT) is associated with significant morbidity and mortality. Given the availability of simple diagnostic methods and the known benefits of strict glycemic control, patients should be screened frequently after organ transplantation. The management of NODAT is multifaceted and aimed at both treatment and prevention of complications. Evaluation of patient risk for post-transplant diabetes mellitus and its complications is an important consideration in initial selection and subsequent modification of the immunosuppressive regimen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033683     DOI: 10.1007/s11892-005-0027-y

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  22 in total

1.  Incidence and predictors of myocardial infarction after kidney transplantation.

Authors:  Krista L Lentine; Daniel C Brennan; Mark A Schnitzler
Journal:  J Am Soc Nephrol       Date:  2004-12-22       Impact factor: 10.121

2.  Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study.

Authors:  Didier Ducloux; Amir Kazory; Jean-Marc Chalopin
Journal:  Transplantation       Date:  2005-02-27       Impact factor: 4.939

3.  Combined effect of growth hormone and cortisol on late posthypoglycemic insulin resistance in humans.

Authors:  J Fowelin; S Attvall; H Von Schenck; U Smith; I Lager
Journal:  Diabetes       Date:  1989-11       Impact factor: 9.461

4.  Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes?

Authors:  A M Miles; N Sumrani; R Horowitz; P Homel; V Maursky; M S Markell; D A Distant; J H Hong; B G Sommer; E A Friedman
Journal:  Transplantation       Date:  1998-02-15       Impact factor: 4.939

5.  Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation.

Authors:  Angelo M de Mattos; Ali J Olyaei; Jonathan C Prather; Muralikrishna S Golconda; John M Barry; Douglas J Norman
Journal:  Kidney Int       Date:  2005-02       Impact factor: 10.612

6.  A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.

Authors:  J D Pirsch; J Miller; M H Deierhoi; F Vincenti; R S Filo
Journal:  Transplantation       Date:  1997-04-15       Impact factor: 4.939

7.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

Authors: 
Journal:  Transplantation       Date:  1996-04-15       Impact factor: 4.939

8.  Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients.

Authors:  Robert S Woodward; Mark A Schnitzler; Jack Baty; Jeffrey A Lowell; Lissa Lopez-Rocafort; Seema Haider; Thasia G Woodworth; Daniel C Brennan
Journal:  Am J Transplant       Date:  2003-05       Impact factor: 8.086

9.  Rapamycin partially prevents insulin resistance induced by chronic insulin treatment.

Authors:  Cathleen E Berg; Brian E Lavan; Cristina M Rondinone
Journal:  Biochem Biophys Res Commun       Date:  2002-05-10       Impact factor: 3.575

10.  Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors.

Authors:  N B Sumrani; V Delaney; Z K Ding; R Davis; P Daskalakis; E A Friedman; K M Butt; J H Hong
Journal:  Transplantation       Date:  1991-02       Impact factor: 4.939

View more
  1 in total

1.  [Sequelae of organ transplantation].

Authors:  S Ciesek; M Manns; C Strassburg
Journal:  Internist (Berl)       Date:  2006-03       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.